Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials

•Recent novel heart failure (HF) trials recommended the use of conventional medical therapy in the enrollment criteria.•62.2% and 35.3% of the patients met the enrollment criteria of the PARADIGM-HF/DAPA-HF and the SHIFT trials.•conventional medical therapy was underutilized (~30%) among patients eligible for novel HF trials.•Use of conventional medical therapy was associated with lower rates of 2-year mortality and HF readmission.•Optimizing conventional medical therapy remains a crucial step in improving the outcomes of HF patients.